All Q4 FY26 results →
OD

OSEL Devices Ltd

Q4 FY26Healthcare Equipment & Supplies

OSEL Devices Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹416
Market cap₹743 Cr
P/E25.4
Updated25 Aug 2026
Read5 min read

What the Q4 FY26 call signalled

2 of 3 strong

RevenueStrong growth
MarginMargins steady
CapexCapex planned

The short version

OSEL expects continued positive growth in sales and revenue for the next few years, maintaining or exceeding recent growth rates. OSEL Devices expects to maintain or exceed the growth achieved in FY26, with positive outlook for at least the next few years.

From OSEL Devices Ltd's Q4 FY26 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Strong growth
  • OSEL expects continued positive growth in sales and revenue for the next few years, maintaining or exceeding recent growth rates.
  • Mobile sales (feature phones) are stable at 60,000-70,000 units monthly, with volumes expected to rise, especially during festivals.
  • FY26 mobile sales amounted to around INR55 crores in H2, with an overall FY26 revenue close to INR300 crores; FY27 target is to surpass INR500 crores.
  • Smartphone manufacturing recently started and is expanding, branded under Philips, with expectations of higher contributions to the top line.
  • Export sales target is INR50 crores for the current year, up from INR23 crores last year.
  • The manufacturing hub at JNPA (Navi Mumbai) will enhance export capabilities and revenues.

2 more points from OSEL Devices Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what OSEL Devices Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • OSEL Devices has planned a capital expenditure project for setting up a manufacturing hub at JNPA (Jawaharlal Nehru Port Authority) in Navi Mumbai.
  • The facility will operate as a Special Economic Zone (SEZ) focusing mainly on LED business, targeting international markets like North America, the Middle East, and Africa.
  • This hub will offer tax advantages, no import duties, and logistic benefits due to its strategic port location.
  • The company has recently received the Letter of Intent (LOI) for this project and is currently working on project planning.
  • Exact capex amount and timelines will be clarified once the project plan is finalized.

2 more points from OSEL Devices Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 3
2Q-Line Biotech
Rev 2Mar 1
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 3Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what OSEL Devices Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • No specific mention of a quantified current order book or pending orders in the transcript.
  • The company has a sizable ongoing engagement in the defense segment with clients such as IMA Military Academy, Naval Academy, Air Force, DRDO, and ISRO.
  • Growth in defense orders is expected with the onboarding of Captain Vivek, who is actively engaging with defense clients.
  • The company received an LOI for the JNPA manufacturing hub project and is working on its implementation, which will add to order inflows.
  • They have ongoing OEM LED manufacturing orders for big brands.
  • Export orders are growing, with INR23 crores done last year and a target of INR50 crores this year.

2 more points from OSEL Devices Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Others in Healthcare Equipment & Supplies this season

  • Vaidya Sane (Q4 FY26)

    170-180 crores driven by higher patient additions, increased hospital utilization, and franchise clinic growth. Key concall takeaways from Vaidya Sane Ayurved…

  • Vasa Denticity Ltd (Q4 FY26)

    The company has a debt line of ₹15 crore available from financial partners. Key concall takeaways from Vasa Denticity Ltd's Q4 FY26 earnings call — and how it…

  • QMS Medical Allied Services Ltd (Q4 FY26)

    INR 13 crores in FY26 to INR 18-20 crores in FY27. Key concall takeaways from QMS Medical's Q4 FY26 earnings call — and how it ranks against sector peers.

  • Poly Medicure Ltd (Q4 FY26)

    Management confident of 15-17% sustainable organic growth over next 3-5 years excluding acquisitions. Key concall takeaways from Poly Medicure Ltd's Q4 FY26…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

OSEL Devices Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were OSEL Devices Ltd Q4 FY26 results?

OSEL expects continued positive growth in sales and revenue for the next few years, maintaining or exceeding recent growth rates. OSEL Devices expects to maintain or exceed the growth achieved in FY26, with positive outlook for at least the next few years.

What is OSEL Devices Ltd share price analysis?

OSEL Devices Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 25.4 with a market cap of ₹743 Cr. Investors should review the full earnings analysis for detailed insights.

Is OSEL Devices Ltd planning capital expenditure?

OSEL Devices has planned a capital expenditure project for setting up a manufacturing hub at JNPA (Jawaharlal Nehru Port Authority) in Navi Mumbai.

Keep OSEL Devices Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.